Patient-Specific Dosimetry Evaluations in Theranostics Software for Internal Radiotherapy

Abstract

In Internal Radiotherapy, radiopharmaceutical dosimetry provides an accurate estimation of absorbed radiation doses to organs at risk and tumours. In this paper Velocity Theranostics (Varian Medical Systems), is investigated. Its performances are compared to OLINDA 2.0 in both an anthropomorphic phantom and a group of patients. Velocity Theranostics was evaluated with a cohort of patients (15) treated with 177Lu radiolabelled peptides. The absorbed doses were calculated for the liver, spleen and kidneys, separately with OLINDA 2.0 and Velocity Theranostics using the same set of images. To reduce the contribution of Time-integrated activities (TIAs) on the results and to merely compare the dose calculation algorithms, the OLINDA 2.0 absorbed doses were calculated using the TIA values calculated in Velocity Theranostics. The absorbed doses from Velocity Theranostics were found to be correlated with the doses from OLINDA 2.0 with the TIAs from Theranostics (Lin’s coefficient = 0.894 and R2 = 0.9531). Absorbed doses from Velocity Theranostics are reliable at least as reliable as those for OLINDA 2.0, with many advantages regarding accuracy of calculations and robustness. In conclusion, the personalisation of dosimetry may be totally fulfilled by computational systems for absorbed dose in internal radiotherapy, equipped with a complete workflow and borrowed from external radiotherapy.

Keywords

• internal radiotherapy
• dosimetry
• ¹⁷⁷Lu
• theranostics
• software